fbpx

Cannabinoid Report: Virodhamine

Virodhamine (also known as O-arachidonoyl ethanolamine or O-AEA) was discovered in 2002 by Porter et al. Virodhamine is one of the body’s many endocannabinoids and is a combination of arachidonic acid and ethanolamine. These two components are formed by an ester linkage, which is the opposite of anandamide’s amide linkage. The name ‘virodhamine’ is based […]

Condition Report: Glaucoma

OVERVIEW In 2017, the National Academies of Science, Engineering & Medicine released a comprehensive report, “The Health Effects of Cannabis & Cannabinoids”, based on the research that had been done to date. Following that valuable report, we’ve been providing weekly Condition Reports on 2018 research for each of the conditions cited in that report, such as […]

Cannabinoid Report: NADA

N-Arachidonoyl dopamine (NADA) is an endogenous cannabinoid that acts as a potent agonist to the body’s CB1 and TRPV1 receptors. NADA was one of the later discovered endocannabinoids, along with 2-AGE and virhodamine. NADA was first proposed as an endocannabinoid in 2000 by T. Bisogno, D. Melck, Bobrov MYu, N. M. Gretskaya, V. V. Bezuglov, […]

Condition Report: Dementia

OVERVIEW In 2017, the National Academies of Science, Engineering & Medicine released a comprehensive report, “The Health Effects of Cannabis & Cannabinoids”, based on the research that had been done to date. Following that valuable report, we’ve been providing weekly Condition Reports on 2018 research for each of the conditions cited in that report, such as […]

Ep. 481: Prof. Cristina Sanchez

Dr. Cristina Sanchez, a molecular biologist at Compultense University in Madrid, Spain, is working to uncover whether or not cannabinoids are useful tools for fighting cancer — not just by combating the negative side effects of chemotherapy, but also by exhibiting actual anti-tumor activity. She notes that, in her and her team’s pre-clinical studies with […]

Cannabinoid Report: 2-AGE

2-Arachidonyl glyceryl ether, often referred to as noladin ether or 2-AGE, is a stable analog of the endogenous cannabinoid 2-AG. It was discovered in 2000 by Lumír Hanuš and his colleagues (Saleh Abu-Lafi, Ester Fride, Aviva Breuer, Zvi Vogel, Deborah E. Shalev, Irina Kustanovich, and Raphael Mechoulam) at the Hebrew University of Jerusalem, in Israel. […]

Condition Report: Huntington’s Disease

OVERVIEW In 2017, the National Academies of Science, Engineering & Medicine released a comprehensive report, “The Health Effects of Cannabis & Cannabinoids”, based on the research that had been done to date. Following that valuable report, we’ve been providing weekly Condition Reports on 2018 research for each of the conditions cited in that report, such as […]

Condition Report: Dystonia

OVERVIEW In 2017, the National Academies of Science, Engineering & Medicine released a comprehensive report, “The Health Effects of Cannabis & Cannabinoids”, based on the research that had been done to date. Following that valuable report, we’ve been providing weekly Condition Reports on 2018 research for each of the conditions cited in that report, such as […]

Cannabinoid Report: 2-AG

2-Arachidonoylglycerol (2-AG) is an endogenous cannabinoid – one of many naturally occurring cannabinoids produced by the mammalian body (2-AG has even been found in cow’s milk and human breast milk.) 2-AG was the second endocannabinoid to be discovered, after anandamide; similarly, it is probably the second most studied endocannabinoid following anandamide. Although researchers from Teikyo […]

Condition Report: Parkinson’s Disease

OVERVIEW In 2017, the National Academies of Science, Engineering & Medicine released a comprehensive report, “The Health Effects of Cannabis & Cannabinoids”, based on the research that had been done to date. Following that valuable report, we’ve been providing weekly Condition Reports on 2018 research for each of the conditions cited in that report, such as […]